In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jago Pharma AG

Division of Vectura Group PLC

Latest From Jago Pharma AG

Skyepharma:Trying To Take Off From a Short Runway

Since 1998, through a series of inexpensive acquisitions, SkyePharma has assembled a wide range of drug delivery technologies, positioning itself as a one stop shop. But the company still has to convince both its customers, and its investors, that it has not sacrificed quality for quantity.
BioPharmaceutical Strategy

Gilead's Metamorphoses

Founded to pursue antisense, Gilead recognized that antisense was too long-term to support the continual financings they knew would be necessary to create a self-sustaining drug business. Thus Gilead began a series of transformations, eventually crafting an image for itself as a near-term antiviral company. Sidebar: Isis Stays Pure: As Gilead has shape-shifted into an antiviral player, Isis has continued to carry the antisense torch. And, says Stanley Crooke, MD, PhD, the company's CEO, Isis' develop
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Vectura Group PLC
  • Senior Management
  • Michael Ashton, CEO
  • Contact Info
  • Jago Pharma AG
    Phone: (41) 61 467 5555
    Eptingerstrasse 51
    Muttenz , CH-4132
    Switzerland
UsernamePublicRestriction

Register